Safety

Ditropan XL (oxybutynin chloride) tablets

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER)

February 2015

Summary View

WARNINGS AND PRECAUTIONS

Central Nervous System Effects
  • Ditropan XL should be used with caution in patients with Parkinson’s disease due to the risk of aggravation of symptoms.
Worsening of Symptoms of Decreased Gastrointestinal Motility in Patients with Autonomic Neuropathy
  • Ditropan XL should be used with caution in patients with autonomic neuropathy due to the risk of aggravation of symptoms of decreased gastrointestinal motility.

DRUG INTERACTIONS

  • Anticholinergic agents may also antagonize the effects of prokinetic agents, such as metoclopramide.

 

November 2012 

Summary View

ADVERSE REACTIONS

  • anorexia, fluid retention, hot flush, dysphonia, dysphagia, frequent bowel movements, chest discomfort, and thirst.  

 

March 2012

Summary View

ADVERSE REACTIONS

Postmarketing Experience
  • glaucoma

 

June 2011

Summary View

WARNINGS

  • Angioedema of the face, lips, tongue and/or larynx has been reported with oxybutynin. In some cases, angioedema occurred after the first dose. Angioedema associated with upper airway swelling may be life-threatening. If involvement of the tongue, hypopharynx, or larynx occurs, oxybutynin should be promptly discontinued and appropriate therapy and/or measures necessary to ensure a patent airway should be promptly provided. 

PRECAUTIONS

Information for Patients
  • Patients should be informed that oxybutynin may produce angioedema that could result in lifethreatening airway obstruction. Patients should be advised to promptly discontinue oxybutynin therapy and seek immediate medical attention if they experience edema of the tongue, edema of the laryngopharynx, or difficulty breathing.

 

Page Last Updated: 03/11/2015
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.